Your browser doesn't support javascript.
loading
節目: 20 | 50 | 100
结果 1 - 6 de 6
过滤器
2.
J Cancer Res Ther ; 2019 Jan; 15(1): 250-251
文章 | IMSEAR | ID: sea-213600

摘要

Although cancers of rectum and kidney are common malignancies, the occurrence of primary synchronous neoplasms of these organs has been reported rarely. Very few case reports are available in literature till date. The relationship between these two events remains unclear, probably because of the rarity of the association. In this report, we describe incidentally detected renal cell carcinoma in an elderly man, during staging workup of rectal adenocarcinoma and both malignancies were surgically managed simultaneously with curative intent.

3.
Indian J Cancer ; 2018 Jul; 55(3): 257-260
文章 | IMSEAR | ID: sea-190364

摘要

BACKGROUND: Recently published prospective clinical trials and two meta-analyses have shown that addition of induction chemotherapy (IC) to concurrent chemoradiation (CRT) could potentially improve outcomes in comparison to CRT alone, in locoregionally advanced nasopharyngeal carcinoma (LANPC). Although it remains unclear which is the best IC regimen to be offered and for how many cycles. Unfortunately, till date, there are no published data from India regarding the outcomes of various commonly used IC regimens before CRT, in LANPC. MATERIALS AND METHODS: Patients diagnosed with LANPC from January 2012 to December 2017, who received three cycles of IC before definitive CRT were reviewed retrospectively. Patients' profile, toxicity of IC, response rates, failure-free survival, and overall survival (OS) were evaluated. RESULTS: A total 34 patients with LANPC who received IC were reviewed. The median age at diagnosis was 36 years, and the majority were males (67.6%, n = 23). Nineteen patients received IC with paclitaxel plus cisplatin regimen (TP) and the remaining 15 patients received IC with docetaxel/paclitaxel plus cisplatin plus 5-FU regimen (TPF). The overall response rates after three cycles of TP and TPF IC were 68.4% and 80%, respectively, and the corresponding rates were 84.2%and 93.3%, respectively, 2 months after completion of CRT. At a median follow-up of 24 months, 2-year failure-free survival and OS for TP arm were 78.9% and 89.5%, and the corresponding rates for TPF arm were 86.7% and 93.3%, respectively. All Grade III–IV toxicities were numerically higher with triplet IC regimen in comparison to doublet regimen. CONCLUSION: In this retrospective analysis, there was no significant difference between taxane-based doublet and triplet IC regimens, in terms of survival outcomes, although Grade III–IV toxicities were numerically higher with triplet IC regimen. Clearly, these hypothesis-generating findings should be tested in a prospective randomized setting.

4.
Indian J Cancer ; 2018 Apr; 55(2): 134-136
文章 | IMSEAR | ID: sea-190334

摘要

BACKGROUND: Skin is the second most common site for extranodal non-Hodgkin's lymphoma (NHL). Most primary cutaneous NHLs are of T-cell origin (70%). Primary cutaneous B-cell lymphoma (PCBCL) is a rare entity. MATERIALS AND METHODS: Patients diagnosed with PCBCL between January 2012 and July 2017 at our center were retrospectively analyzed. RESULTS: Eight patients of PCBCL were diagnosed. Three patients (37.5%) were males while 5 patients (62.5%) were females. The median age at diagnosis was 45 years (range, 18–60 years). Scalp was the most common site of involvement (50% of the patients). Diffuse large B-cell lymphoma (DLBCL) was the most common histology (63%), with leg-type DLBCL diagnosed in 1 patient. Two patients had primary cutaneous follicle center lymphoma, whereas the remaining 1 patient had precursor B-lymphoblastic lymphoma. All 5 DLBCL cases were treated with CHOP chemotherapy, and rituximab was given to 3 patients. Of the primary cutaneous follicle center lymphomas, 1 patient with stage II disease was treated with CHOP and is alive without recurrence for the past 5 years, whereas the other patient is on observation alone. The patient with precursor B-lymphoblastic lymphoma was started on MCP-841 protocol; however, the patient did not complete the treatment and died after 11 months. CONCLUSIONS: PCBCL is a heterogeneous group of diseases and dividing them into subtypes, based on morphology and immunophenotype, has therapeutic implications.

5.
J Cancer Res Ther ; 2008 Apr-Jun; 4(2): 93-4
文章 在 英语 | IMSEAR | ID: sea-111423

摘要

Bone is an uncommon site of metastasis in patients with hepatocellular carcinoma (HCC), and often overlooked. We report two cases that had isolated bone metastasis; one of them had prolonged disease-free survival. The present series, along with the literature review, reinforces the idea that HCC should be considered in the differential diagnoses in patients presenting with metastases in bone. The presence of isolated bone metastases need not necessarily indicate poor prognosis, and all such patients need to be offered chemotherapy and at least one of the bone-directed therapies (either local radiation in cases of localized disease or bisphosphonates in the presence of extensive disease) as they may have a better outcome with therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/drug therapy , Brain Neoplasms/diagnosis , Carcinoma, Hepatocellular/drug therapy , Cisplatin/administration & dosage , Diphosphonates/administration & dosage , Doxorubicin/administration & dosage , Fatal Outcome , Female , Humans , Imidazoles/administration & dosage , Liver Neoplasms/drug therapy , Male , Middle Aged , Neoplasm Staging , Palliative Care , Radiography, Thoracic
6.
J Indian Med Assoc ; 2003 Jul; 101(7): 418-9
文章 在 英语 | IMSEAR | ID: sea-103033

摘要

Cancer, the dreaded killer disease, has its aetiology in several factors like genetic, environmental, diet habits, etc. Age over 65 years is generally considered elderly and the cancer incidence increases with age. Cancer is second to cardiovascular disease for the cause of death in the elderly. The behaviour of certain cancers also differ in the elderly thus adding to the ultimate outcome that is usually confounded by several comorbid illnesses. The prognostic factor varies with type of cancer. Older patients with Hodgkin's disease and acute myeloid leukaemia do worse than breast cancer. Radiation therapy is well tolerated by the elderly.


Subject(s)
Aged , Aging , Humans , Neoplasms/therapy
搜索明细